Physician profile
Mitzi Carter
NPI 1821001421
$5,387.98
in general payments reported to CMS, 2019-2025
24 companies · $492 in 2025
The $492 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $461 · 2022: $1,471 · 2023: $855 · 2024: $2,108 · 2025: $492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,721 · Travel and Lodging: $1,476 · Education: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,720.83 |
| Travel and Lodging | $1,475.66 |
| Education | $258.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,587.65 | 2022-2024 | |
| Janssen Biotech, INC. | $667.01 | 2021-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $279.23 | 2021-2023 | |
| Pfizer INC. | $275.95 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $252.11 | 2022-2023 | Sotyktu |
| Genzyme Corporation | $234.88 | 2021-2025 | |
| Ucb, INC. | $199.31 | 2021-2023 | Cimzia |
| Sun Pharmaceutical Industries INC. | $199.03 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.91 | 2023 | Spevigo |
| Regeneron Healthcare Solutions, INC. | $84.46 | 2021-2022 | |
| Lilly USA, LLC | $70.45 | 2021-2023 | Olumiant, Taltz |
| Dermavant Sciences, INC. | $67.16 | 2023 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $63.21 | 2021-2023 | Jublia |
| Galderma Laboratories, L.P. | $52.63 | 2021-2022 | |
| Arcutis Biotherapeutics, INC. | $47.81 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $39.47 | 2022-2023 | Opzelura |
| Mayne Pharma Commercial LLC | $31.70 | 2023 | |
| Baxter Healthcare | $29.00 | 2024 | Tisseel |
| Organogenesis INC. | $22.26 | 2023 | Puraply |
| Amgen INC. | $21.27 | 2023 | Otezla |
| Medtronic, INC. | $18.95 | 2024 | Progrip |
| Botanix Sb INC | $18.06 | 2025 | Sofdra |
| Almirall LLC | $17.42 | 2021 | |
| Dermira, INC. | $12.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitzi Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.